[Monoclonal antibodies for treating infectious diseases].
Monoclonal antibodies (mAb) are attractive biologic drugs because of their specificity and well understood mechanisms of action. So far, most mAb have been developed for treating cancers or immunological disorders. However, the antibiotic resistance crisis, emerging viral diseases and bioterrorism have increased the development of anti-infectious mAb, for which more than twenty clinical trials are in progress to evaluate their safety and efficacy. The synergies obtained using combinations of anti-infectious mAb and small molecule drugs will certainly offer new opportunities for the treatment of infectious diseases.
Klinguer-Hamour
Christine
C
Centre d'immunologie Pierre Fabre, 5, avenue Napoléon III, BP 60497, 74160 Saint-Julien en Genevois, France. christine.klinguer.hamour@pierre-fabre.com
Caussanel
Véronique
V
Beck
Alain
A
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000188:drug therapy*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000276:immunology
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal